ADE LLC’s Novartis NVS Stock Holding History

ADE LLC’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-503	Closed	-$43K	–	266
2021 Q1	$43K	Hold	503	–	–	0.04%	133
2020 Q4	$47K	Buy	+503	New	+$44K	0.04%	163

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ADE LLC's NVS Position: Q2 2021 in Review

ADE LLC sold out of Novartis (NVS) in Q2 2021, closing a stake of 503 shares — an estimated $43K sold.

ADE LLC first reported a position in NVS in Q4 2020 and held it in 2 quarters. The position peaked at $47K in Q4 2020. 1,119 funds tracked by Wall St. Rank hold NVS as of Q2 2021.

ADE LLC reported no remaining Novartis position as of Q2 2021 after selling out during the quarter.
ADE LLC sold 503 Novartis shares in Q2 2021, an estimated $43K.
ADE LLC first reported a position in Novartis in Q4 2020 and held it in 2 quarters.
ADE LLC's Novartis position peaked at $47K in Q4 2020.
1,119 funds tracked by Wall St. Rank held Novartis as of Q2 2021.

Based on ADE LLC's 13F filing for Q2 2021, filed 27 Jul 2021.